NeoGenomics, Inc. - Common Stock — Balance Sheet (NASDAQ:NEO) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 988.33 M1.87 B1.74 B1.68 B1.64 B1.36 B Total liabilities 294.04 M761.5 M742.01 M739.69 M735.7 M523.27 M Total equity 694.29 M1.11 B998.02 M941.54 M902.34 M836.56 M Total liabilities & shareholders' equities 988.33 M1.87 B1.74 B1.68 B1.64 B1.36 B Total debt 170.96 M533.62 M535.39 M538.2 M340.33 M341.86 M Net debt -125.3 M18.23 M272.21 M195.71 M340.33 M341.86 M

News

1X launches new generation NEO manipulator, reportedly achieves near-human dexterity and force control

Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?

Indian tech tycoon bets $30M of his own money to build AI alternative to Microsoft Office

Biotech Is The Rate Cut Trade In Disguise

The Disinflation Trade Has A New Address: Genomics

NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine (TEM)

NeoGenomics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:NEO) 2026-04-28

William Blair reiterates Market Perform on Neogenomics stock after Medicare coverage decision

Neogenomics stock gets Medicare coverage for blood-based test

Neogenomics stock gets MolDX reimbursement for cancer test

NeoGenomics’ PanTracer LBx test receives Medicare coverage